TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04949113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant ipilimumab + nivolumab
Description: 2 cycles ipilimumab (80mg) + nivolumab (240mg) every 3 weeks followed by total lymph node dissection
Study: NCT06337578

Intervention type: BEHAVIORAL
Intervention: Telephone-based neuropsychological assessment - ALS
Description: ALS patients will be administered the following TBCS tests:~* ALS Cognitive Behavioral Screen-Phone Version;~* Telephone-based Frontal Assessment Battery;~* Telephone Language Screener;~* Telephone-based Verbal Fluency Battery;~This group will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:~* Activities of Daily Living;~* Instrumental Activities of Daily Living;~* Amsterdam IADL Questionnaire - Short Version;~* Caregiver Behavioral Questionnaire;~* ECAS-Carer Interview.

Intervention type: BEHAVIORAL
Intervention: Telephone-based neuropsychological assessment - AD, LBD, FTD and CVD
Description: AD, DLB, FTD and CVD patients will be administered the following TBCS tests:~* Telephone Interview for Cognitive Status;~* Telephone-based Frontal Assessment Battery;~* Telephone Language Screener;~* Telephone-based Verbal Fluency Battery;~These groups will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:~* Activities of Daily Living;~* Instrumental Activities of Daily Living;~* Amsterdam IADL Questionnaire - Short Version;~* Neuropsychiatric Inventory;~* Frontal Behavioural Inventory.
Study: NCT05960656

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30mg
Description: A medication used in the management and treatment of type 2 diabetes mellitus. It is in the thiazolidinedione class of medications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30mg + Empagliflozin (25 mg)
Description: Combination of two medications used in the management and treatment of type 2 diabetes mellitus in the thiazolidinedione and sodium-glucose co-transporter (SGLT-2) class of medications, respectively.
Study: NCT05489276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2825 injection
Description: TQB2825 injection is a bi-specific, humanized antibody against CD3×CD20, with the structure ratio of anti-CD3 to anti-CD20 of 1:2. It has two asymmetric Fab ends and a complete Fc end, and is a natural IgG4 subtype with weak antibody-dependent cell-mediated cytotoxicity or complement dependent cytotoxicityfunction. By bridging CD3 and CD20, TQB2825 injection induces T cell activation to promote T cell proliferation/expansion, promote the formation of cytolytic synapses, and cause cytotoxic T cells to release perforin and granase, thereby killing CD20 positive tumor cells. Therefore, TQB2825 injection is intended for the treatment of CD20 positive hematologic tumors, including but not limited to lymphoma, leukemia and myeloma.
Study: NCT06337578

Intervention type: BEHAVIORAL
Intervention: Telephone-based neuropsychological assessment - AD, LBD, FTD and CVD
Description: AD, DLB, FTD and CVD patients will be administered the following TBCS tests:~* Telephone Interview for Cognitive Status;~* Telephone-based Frontal Assessment Battery;~* Telephone Language Screener;~* Telephone-based Verbal Fluency Battery;~These groups will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:~* Activities of Daily Living;~* Instrumental Activities of Daily Living;~* Amsterdam IADL Questionnaire - Short Version;~* Neuropsychiatric Inventory;~* Frontal Behavioural Inventory.

Intervention type: BEHAVIORAL
Intervention: Telephone-based neuropsychological assessment - AD, LBD, FTD and CVD
Description: AD, DLB, FTD and CVD patients will be administered the following TBCS tests:~* Telephone Interview for Cognitive Status;~* Telephone-based Frontal Assessment Battery;~* Telephone Language Screener;~* Telephone-based Verbal Fluency Battery;~These groups will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:~* Activities of Daily Living;~* Instrumental Activities of Daily Living;~* Amsterdam IADL Questionnaire - Short Version;~* Neuropsychiatric Inventory;~* Frontal Behavioural Inventory.

Intervention type: BEHAVIORAL
Intervention: Telephone-based neuropsychological assessment - AD, LBD, FTD and CVD
Description: AD, DLB, FTD and CVD patients will be administered the following TBCS tests:~* Telephone Interview for Cognitive Status;~* Telephone-based Frontal Assessment Battery;~* Telephone Language Screener;~* Telephone-based Verbal Fluency Battery;~These groups will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:~* Activities of Daily Living;~* Instrumental Activities of Daily Living;~* Amsterdam IADL Questionnaire - Short Version;~* Neuropsychiatric Inventory;~* Frontal Behavioural Inventory.

Intervention type: BEHAVIORAL
Intervention: Telephone-based and in-person cognitive screening - NIs
Description: NIs will undergo the Telephone Interview for Cognitive Status over the telephone and will be additionally administered, in person, the following cognitive screeners:~* Mini-Mental State Examination~* Montreal Cognitive Assessment~* In-Person Telephone Interview for Cognitive Status in person.
Study: NCT04949113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant nivolumab
Description: Upfront total lymph node dissection followed by 12 cycles of nivolumab (480mg) every 4 weeks.
Study: NCT06031545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long peripheral venous catheters for use
Description: Long peripheral venous catheters for use during the perioperative period in obese patients

Intervention type: OTHER
Group type: OTHER
Intervention: Midline catheter
Description: Midline catheters for use during the perioperative period in obese patients
Study: NCT06000826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celsi Warmer
Description: During the study, research participants will receive thermal care via the Celsi Warmer. Aside from thermal treatment, research participants will receive the standard of care from the neonatal unit, and will also be closely monitored by study personnel throughout the study. The results from this study will allow the research team to determine if the Celsi Warmer is an effective tool for warming and monitoring newborns in wards of low-resource hospitals. The research team hopes to demonstrate that the Celsi Warmer is effective for the appropriate treatment of newborn hypothermia in hospitals in low-resource settings.
Study: NCT04657302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive 1000 mg of intravenous (IV) obinutuzumab on Cycle 1 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Participants will receive 2.5 mg of IV glofitamab Cycle 1 Day 8, 10 mg at Cycle 1 Day 15, and 30 mg on Day 1 of Cycles 2-12 Q3W (cycle length = 21 days).
Study: NCT04988997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vurolenatide 50mg/PBO
Description: Vurolenatide - 50 mg biweekly SC administration, PBO alternate weeks
Study: NCT04657302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).
Study: NCT05060003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is provided by Genentech.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab is provided by Genentech.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab is provided by Genentech.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Signatera Assay
Description: * To detect residual disease or to determine cancer recurrence with ctDNA~* Step 2 screening (4-12 weeks after date of surgery), cycle 3 day 1, cycle 6 day 1, cycle 9 day 1, cycle 12 day 1, and end of treatment (optional)
Study: NCT04988997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vurolenatide 100mg/PBO
Description: Vurolenatide - 100 mg biweekly SC administration, PBO alternate weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vurolenatide 50/50 mg
Description: Vurolenatide - 50 mg weekly SC administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PBO - weekly SC administration
Study: NCT05060003

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Signatera Assay
Description: * To detect residual disease or to determine cancer recurrence with ctDNA~* Step 2 screening (4-12 weeks after date of surgery), cycle 3 day 1, cycle 6 day 1, cycle 9 day 1, cycle 12 day 1, and end of treatment (optional)
Study: NCT05408403

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regional anesthesia TFPB
Description: Transversalis Fascia Plane Block will be performed with 25 mL of 0.25% bupivacaine,after the end of cesarean surgery before extubation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regional anesthesia QLB
Description: Anterior Quadratus Lumborum Block will be performed with 25 mL of 0.25% bupivacaine, after the end of cesarean surgery before extubation.
Study: NCT04810429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Incobotulinumoxin A
Description: XEOMIN® (incobotulinumtoxinA) is an approved medication that inhibits the release of acetylcholine and muscle blockage. Xeomin is indicated for the symptomatic treatment of blepharospasm and hemifacial spasm, cervical dystonia of a predominantly rotational type (spasmodic torticollis), spasticity of the upper limbs and chronic sialorrhea due to neurological changes. Xeomin comes as a white powder for solution for injection. When dissolved Xeomin is a clear, colorless solution that does not contain particles. Xeomin is reconstituted before use with sterile sodium chloride 9 mg / ml (0.9%) solution, without preservatives, for injections.~The active substance is Clostridium botulinum type A neurotoxin (150 kD), without complexing proteins. The other components are human albumin and sucrose.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TMJ surgical arthroscopy
Description: TMJ arthroscopy is a minimal invasive surgical technique for different types of temporomandibular joint (TMJ) internal derangements. Besides the acceptable outcomes of TMJ arthroscopy, the authors believe that adding to this treatment a single injection of BTXA into the temporalis and masseter muscles could reduce joint loading, improving TMJ arthroscopic results.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TMJ surgical arthroscopy
Description: TMJ arthroscopy is a minimal invasive surgical technique for different types of temporomandibular joint (TMJ) internal derangements. Besides the acceptable outcomes of TMJ arthroscopy, the authors believe that adding to this treatment a single injection of BTXA into the temporalis and masseter muscles could reduce joint loading, improving TMJ arthroscopic results.
Study: NCT05742204

Intervention type: OTHER
Intervention: Plasma protein biomarker analysis
Description: Plasma samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment.We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients .

Intervention type: OTHER
Intervention: Plasma protein biomarker analysis
Description: Plasma samples of control subjects were collected.
Study: NCT04687423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-011
Description: FCN-011 will be given orally in ascending doses starting at 50 mg Q12h or 100mg QD until the maximum tolerated dose or recommended dose is reached.
Study: NCT05900570

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urodynamic testing with and without pudendal nerve stimulation
Description: A urodynamic test with and without neurostimulation will be conducted. The external neurostimulator device settings will be adjusted to deliver acute nerve stimulation per the individual tolerance level to assess the effect on urethral pressure. A leak point pressure (LLP) during Valsalva maneuver will be assessed with and without acute nerve stimulation.
Study: NCT04932291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vafidemstat
Description: 1.2mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule
Study: NCT05749302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Al18F-NOTA-FAPI
Description: Al18F-NOTA-FAPI was injected into the patients before the PET/CT scans
Study: NCT05669560

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PerioProtect ™= plastic tray +1.7% hydrogen peroxide
Description: Subjects will receive PerioProtect ™ in adjunct to mechanical therapy. 15minutes, twice a day, for 3 months.
Study: NCT05608122

Intervention type: OTHER
Intervention: Obervation
Description: This study is an observational study without any intervention

Intervention type: OTHER
Intervention: Obervation
Description: This study is an observational study without any intervention
Study: NCT04738695

Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-care rapid anti-SARS-CoV-2 antibody test (Orient Gene Biotech) and Dry Blood Spot collection (Euroimmun)
Description: Bimonthly finger pricks with collection of 1-10 drops of capillary blood for detection of anti-SARS-CoV-2 immune markers
Study: NCT06443723

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: USG, blood tests, waist, hip, height and blood pressure measurements
Description: MAFLD is defined as hepatic steatosis entity in addition to the presence of overweight or obesity, DM, or evidence of metabolic dysfunction.~Metabolic dysfunction (two or more of the following)~1. waist circumference ≥ 90 cm in men and 88 cm in women,~2. blood pressure ≥ 130/85 mmHg or on specific drug treatment,~3. plasma triglycerides (TG) ≥ 150 mg/dl or on specific drug treatment,~4. plasma high-density lipoprotein cholesterol (HDL-C) \< 40 mg/dl for men and 50 mg/dl for women or on specific drug treatment,~5. prediabetes (FBS 100 to 125 mg/dl or HbA1c 5.7 to 6.4%),~6. homeostasis model assessment of insulin resistance (HOMA-IR) score ≥ 2.5.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: USG, blood tests, waist, hip, height and blood pressure measurements
Description: MAFLD is defined as hepatic steatosis entity in addition to the presence of overweight or obesity, DM, or evidence of metabolic dysfunction.~Metabolic dysfunction (two or more of the following)~1. waist circumference ≥ 90 cm in men and 88 cm in women,~2. blood pressure ≥ 130/85 mmHg or on specific drug treatment,~3. plasma triglycerides (TG) ≥ 150 mg/dl or on specific drug treatment,~4. plasma high-density lipoprotein cholesterol (HDL-C) \< 40 mg/dl for men and 50 mg/dl for women or on specific drug treatment,~5. prediabetes (FBS 100 to 125 mg/dl or HbA1c 5.7 to 6.4%),~6. homeostasis model assessment of insulin resistance (HOMA-IR) score ≥ 2.5.
Study: NCT05986227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: toripalimab FOLFOX
Description: Toripalimab（3mg/kg, q2w, IV）oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV) and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab FOLFOX
Description: Toripalimab（3mg/kg, q2w, IV）oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV) and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab FOLFOX
Description: Toripalimab（3mg/kg, q2w, IV）oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV) and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab FOLFOX
Description: Toripalimab（3mg/kg, q2w, IV）oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV) and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h)
Study: NCT04932915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Niclosamide is a broad spectrum, host targeting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide solution is administered directly to the nasal cavity via a nasal spray.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo formulation contains purified water, sodium chloride as common isotonizing agent and the FAO/WHO approved colorant FD\&C Red 40 to match the red-orange colour of the active solution. The solution is administered directly to the nasal cavity via a nasal spray.
Study: NCT05496244

Intervention type: DEVICE
Intervention: Laparoscopy
Description: Laparoscopic surgery

Intervention type: DEVICE
Intervention: Robotic-assisted surgery
Description: Robotic-assisted surgery
Study: NCT05775133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICG
Description: Patient will receive a standard dose of indocyanine green (ICG) 45 minutes prior to surgery. ActivSight will be used during laparoscopic cholecystectomy - the surgeon will perform the procedure in their standard fashion.~Video data will be analyzed in real-time by Activ Surgical's ActivInsight surgical artificial intelligence platform to identify anatomic structures and surgical phase. The surgeon will be blinded to this information, and will see the standard screens and information they do when performing the procedure in a non-study setting.
Study: NCT05368493

Intervention type: OTHER
Group type: OTHER
Intervention: MRI task
Description: Task fMRI (Simon) \[ Time Frame: Children will undergo MRI scans when they are 6-11 years of age. \] Children will also complete a task, which will allow exploratory analyses of the functionality of attention-related neural circuits. The Simon fMRI task is a non-verbal task equivalent to the Stroop that tests sustained attention and inhibitory control and discriminates children with and without ADHD. Exploratory fMRI time-series data for each participant will be modeled using a general linear model with 3 predictors: congruent correct, incongruent correct, and incorrect. Contrast images for each participant (e.g., incongruent-minus-congruent) will be generated and entered into a group-level random-effects model. Analyses are exploratory, and will focus on frontal lobe activity during each type of trial.
Study: NCT05726396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMT
Description: A single loading dose of RMT capsules containing \~5 x 10 11 bacteria on day 1 followed by 2 x 10 11 bacteria daily for 6 days. The RMT capsule preparation (\~2-5 capsules, size 00) is self-administered on an empty stomach with at least one glass of water. Clear liquids are allowed, and food can be resumed 2 hours after administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive an identical looking placebo capsules daily for 7 days (i.e 5 placebo capsules on day 1), followed by 2 placebo capsules daily from Day 2-7. The placebo capsule preparation is self-administered on an empty stomach with at least one glass of water. Clear liquids are allowed, and food can be resumed 2 hours after administration.
Study: NCT04913142

Intervention type: OTHER
Intervention: Fecal and oral samples
Description: oral and rectal swab from patients hospitalized at day 1, each 7 days and at the end of their ICU stay

Intervention type: OTHER
Intervention: Fecal and oral samples
Description: oral and rectal swab from patients hospitalized at day 1, each 7 days and at the end of their ICU stay
Study: NCT06025812

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
Description: Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
Description: Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant novel coronavirus protein vaccine (CHO cells)
Description: Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant new coronavirus vaccine (CHO cells).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant novel coronavirus protein vaccine (CHO cells)
Description: Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant new coronavirus vaccine (CHO cells).
Study: NCT06506539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placental Extract
Description: add placental extract gel as a local delivery drug in periodontal pocket
Study: NCT05733728

Intervention type: OTHER
Intervention: any therapy suitable
Description: any therapy suitable
Study: NCT05691023

Intervention type: DEVICE
Intervention: Vivistim System
Description: Paired VNS during rehabilitation, facilitated by a rehab therapist in the subject's home (at-home treatment)
Study: NCT06137027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol Oil
Description: Cannabidiol oil will be administered sublingually 2-3 hours preoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered sublingually 2-3 hours preoperatively
Study: NCT06148025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: 0.1ml injected intradermally over the distal insertion of the deltoid muscle onto the humerus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: 0.1ml injected intradermally over the distal insertion of the deltoid muscle onto the humerus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: 0.1ml injected intradermally over the distal insertion of the deltoid muscle onto the humerus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: 0.1ml injected intradermally over the distal insertion of the deltoid muscle onto the humerus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: 0.1ml injected intradermally over the distal insertion of the deltoid muscle onto the humerus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: 0.1ml injected intradermally over the distal insertion of the deltoid muscle onto the humerus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever vaccine
Description: 0.5ml injected subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever vaccine
Description: 0.5ml injected subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever vaccine
Description: 0.5ml injected subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever vaccine
Description: 0.5ml injected subcutaneously